Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Crizotinib (Xalkori)
DRUG
3 trials
Sponsors
M.D. Anderson Cancer Center
, Pfizer
, IDEAYA Biosciences
Conditions
Advanced Cancers
Non-small Cell Lung Cancer
Uveal Melanoma
Phase 1
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
Terminated
NCT01548144
M.D. Anderson Cancer Center
Advanced Cancers
Start: 2012-04-30
End: 2021-08-26
Updated: 2021-09-13
Phase 3
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
Recruiting
NCT07804186
IDEAYA Biosciences
Uveal Melanoma
Start: 2026-09-01
End: 2034-04-01
Target: 450
Updated: 2026-09-15
Unknown Phase
Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)
Completed
NCT01597258
Pfizer
Non-small Cell Lung Cancer
Start: 2012-05-29
End: 2018-03-16
Updated: 2019-09-13
Related Papers
Treatment status and safety of crizotinib in 2028 Japanese patients with ALK-positive NSCLC in clinical settings
Japanese Journal of Clinical Oncology
2019-04-09
15 citations
STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.
2015-06-11
77 citations